Bausch + Lomb Corporation announced the launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) with Intermediate Optimized (IO) optics in the United States. enVista Aspire combines novel optics, which are designed for a broader depth of focus, with the proven benefits of the enVista platform to address patient’s vision needs in today’s modern, digital world.
“enVista IOLs are well known by cataract surgeons who have chosen the platform for millions of patients worldwide,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The added feature of broader depth of focus makes enVista Aspire a compelling new option for the many patients who use digital devices on a daily basis.”
Unlike conventional spherical monofocal IOLs and lower-order aspheric IOLs, enVista Aspire optics allow for a range of vision beyond one focal point.
Like enVista MX60E, enVista Aspire offers a glistening-free optic material and controlled, efficient unfolding through Bausch + Lomb’s proprietary StableFlex Technology, which aids optic recovery.
For patients with astigmatism, enVista Aspire Toric IOLs provide a proven option for treatment of their astigmatism during cataract surgery. Featuring a low cylinder design, enVista is the only toric IOL platform available to treat less than one diopter of astigmatism at the corneal plane.
The unique AccuSet haptic design allows for exceptional rotational stability, an important attribute for toric lenses.
“enVista monofocal and toric lenses consistently deliver excellent results, and I’m looking forward to having access to a lens that allows for a broader depth of focus,” said Alice Epitropoulos, MD, cataract and refractive surgeon, Columbus, Ohio. “Cataract surgery is all about meeting each patient’s unique needs, considering various factors, including their lifestyle, which increasingly involves extensive screen time. Having a variety of options that address today’s demands is absolutely critical.”
Indications and Important Safety Information for enVista Aspire hydrophobic acrylic IOL
Indications: The enVista Aspire hydrophobic acrylic IOL (non-preloaded model EA) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia following removal of a cataractous lens.
Device Description: The Aspire IOL uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus. However, clinically meaningful extension of the depth of focus has not been demonstrated in clinical trials.
Warnings
As with any surgical procedure, there is risk involved. Physicians considering IOL implantation under any of the following circumstances should weigh the potential risk/benefit ratio: (1) Recurrent severe anterior or posterior segment inflammation or uveitis; (2) Patients in whom the IOL may affect the ability to observe, diagnose, or treat posterior segment diseases; (3) Surgical difficulties at the time of cataract extraction, which might increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss); (4) A distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is not possible; (5) Circumstances that would result in damage to the endothelium during implantation; (6) Suspected microbial infection; (7) Patients in whom neither the posterior capsule nor zonules are intact enough to provide support.
Precautions
- Neither the safety and effectiveness, nor the effects of the Aspire IOL optical design on depth of focus, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have been evaluated clinically. MTF testing of the Aspire IOL optical design (used in model ETA) may aid the surgeon in understanding the theoretical image quality expected with the Aspire IOL compared to the enVista monofocal IOL MX60E. However, these do not fully assess all aspects of clinical difficulties under all conditions. Surgeons must weigh the potential benefits of the modified optical design of the Aspire IOL (model ETA) against the potential for risks associated with a degradation in vision quality and the lack of clinical data to characterize the impact of the Aspire IOL optical design on contrast sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain pre-existing ocular conditions (prior corneal refractive surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc.) or intraoperative conditions (posterior capsular rupture, complications in which the IOL stability could be compromised, inability to place IOL in capsular bag, etc).
- The safety and effectiveness of the IOL have not been substantiated in patients with pre-existing ocular conditions and intraoperative complications. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting an IOL in a patient with one or more of these conditions. Physicians considering IOL implantation in such patients should explore the use of alternative methods of aphakic correction and consider IOL implantation only if alternatives are deemed unsatisfactory in meeting the needs of the patient.
- Patients with preoperative problems, such as corneal endothelial disease, abnormal cornea, macular degeneration, retinal degeneration, glaucoma, and chronic drug miosis may not achieve the visual acuity of patients without such problems. The physician must determine the benefits to be derived from IOL implantation when such conditions exist.
Adverse Events: As with any surgical procedure, there is risk involved. Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon transient or persistent glaucoma, and secondary surgical intervention. Secondary surgical interventions include but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.
CAUTION: Federal law restricts this device to sale by or on the order of a physician.
ATTENTION: This is not all you need to know. Please refer to the Directions For Use labeling for a complete listing of indications, full risk and safety information, clinical study information, etc.